$PLX
Protalix BioTherapeutics, Inc. Stock $plx

$plx Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-K Financial Statement

#000114420416086642 Filed on March 08, 2016

Income Statement

Concept	2016 Q1	2015	2014 Q4
Revenue	$679.0K	$4.364M	-$10.25M
YoY Change	-84.54%	23.87%	-1.35%
Cost Of Revenue	$523.0K	$730.0K	-$6.850M
YoY Change	-78.21%	15.87%	76.55%
Gross Profit	$156.0K	$3.634M	-$3.410M
YoY Change	-94.22%	25.61%	-47.7%
Gross Profit Margin	22.97%	83.27%
Selling, General & Admin	$1.995M	$7.279M	$1.940M
YoY Change	9.5%	-21.12%	-2.51%
% of Gross Profit	1278.85%	200.3%
Research & Development	$7.334M	$24.89M	$4.070M
YoY Change	20.23%	-9.0%
% of Gross Profit	4701.28%	684.89%
Depreciation & Amortization	$516.0K	$2.370M	$720.0K
YoY Change	-16.23%	-24.52%	-15.29%
% of Gross Profit	330.77%	65.22%
Operating Expenses	$9.329M	$32.17M	$7.030M
YoY Change	17.76%	-12.06%	-33.55%
Operating Profit	-$7.864M	-$23.67M	-$10.44M
YoY Change	46.06%	-17.12%	-38.95%
Interest Expense	-$660.0K	$3.549M	-$1.390M
YoY Change	-41.59%	0.0%	87.84%
% of Operating Profit
Other Income/Expense, Net	-$662.0K	-$3.612M
YoY Change	-41.36%	-23.78%
Pretax Income	-$8.530M	-$27.28M	-$11.82M
YoY Change	31.03%	-18.08%	-33.71%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$8.598M	$58.04M	-$8.470M
YoY Change	43.97%	-293.82%	-22.22%
Net Earnings / Revenue	-1266.27%	1329.9%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.86	$6.11	-$0.89
COMMON SHARES
Basic Shares Outstanding	99.81M shares		93.67M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q1	2015	2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$66.70M	$77.00M	$54.80M
YoY Change	38.96%	37.5%	-36.57%
Cash & Equivalents	$66.70M	$76.40M	$54.77M
Short-Term Investments		$600.0K
Other Short-Term Assets	$3.900M	$3.100M	$2.202M
YoY Change	33.06%	-49.18%	51.13%
Inventory	$5.700M	$5.800M	$3.451M
Prepaid Expenses			$369.0K
Receivables			$1.884M
Other Receivables
Total Short-Term Assets	$76.30M	$85.90M	$65.52M
YoY Change	28.05%	31.15%	-33.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.300M	$9.700M	$11.28M
YoY Change	-14.2%	-14.16%	-17.72%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.700M	$1.600M	$1.600M
YoY Change	6.25%	0.0%	-5.88%
Total Long-Term Assets	$11.00M	$11.40M	$12.84M
YoY Change	-11.75%	-11.63%	-16.8%
TOTAL ASSETS
Total Short-Term Assets	$76.30M	$85.90M	$65.52M
Total Long-Term Assets	$11.00M	$11.40M	$12.84M
Total Assets	$87.30M	$97.30M	$78.36M
YoY Change	21.17%	24.11%	-30.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.900M	$3.600M	$6.802M
YoY Change	-25.0%	-5.26%	28.34%
Accrued Expenses		$3.600M	$3.113M
YoY Change		-32.08%	74.4%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.300M	$11.20M	$64.35M
YoY Change	-64.97%	-82.61%	141.06%
LONG-TERM LIABILITIES
Long-Term Debt	$72.20M	$72.10M	$912.0K
YoY Change	6.8%	6.97%	-61.54%
Other Long-Term Liabilities	$3.200M	$3.000M	$2.300M
YoY Change	-91.82%	30.43%	-95.05%
Total Long-Term Liabilities	$75.40M	$75.10M	$69.60M
YoY Change	-29.3%	7.75%	-38.72%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.300M	$11.20M	$64.35M
Total Long-Term Liabilities	$75.40M	$75.10M	$69.60M
Total Liabilities	$84.70M	$86.40M	$134.0M
YoY Change	-36.41%	-35.52%	-4.51%
SHAREHOLDERS EQUITY
Retained Earnings			-$241.3M
YoY Change			14.17%
Common Stock			$185.7M
YoY Change			0.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.650M	$10.90M	-$55.60M
YoY Change
Total Liabilities & Shareholders Equity	$87.30M	$97.30M	$78.36M
YoY Change	21.17%	24.11%	-30.86%

Cashflow Statement

Concept	2016 Q1	2015	2014 Q4
OPERATING ACTIVITIES
Net Income	-$8.598M	$58.04M	-$8.470M
YoY Change	43.97%	-293.82%	-22.22%
Depreciation, Depletion And Amortization	$516.0K	$2.370M	$720.0K
YoY Change	-16.23%	-24.52%	-15.29%
Cash From Operating Activities	-$9.625M	-$24.28M	-$4.870M
YoY Change	49.9%	-17.07%	2.74%
INVESTING ACTIVITIES
Capital Expenditures	$251.0K	$464.0K	$170.0K
YoY Change	153.54%	-40.89%	-22.73%
Acquisitions
YoY Change
Other Investing Activities	$42.00K	$96.00K	$0.00
YoY Change		-29.93%	-100.0%
Cash From Investing Activities	-$293.0K	$39.39M	-$170.0K
YoY Change	195.96%	-4034.77%	-37.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		$6.635M	10.00K
YoY Change		13170.0%	-114.29%
NET CHANGE
Cash From Operating Activities	-$9.625M	-$24.28M	-4.870M
Cash From Investing Activities	-$293.0K	$39.39M	-170.0K
Cash From Financing Activities		$6.635M	10.00K
Net Change In Cash	-$9.918M	$21.74M	-5.030M
YoY Change	52.12%	-171.79%	-0.98%
FREE CASH FLOW
Cash From Operating Activities	-$9.625M	-$24.28M	-$4.870M
Capital Expenditures	$251.0K	$464.0K	$170.0K
Free Cash Flow	-$9.876M	-$24.75M	-$5.040M
YoY Change	51.47%	-17.69%	1.61%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	124000000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	4089000	USD
CY2013	us-gaap	Revenues Revenues	0	USD
CY2014	us-gaap	Revenues Revenues	3523000	USD
CY2015	us-gaap	Revenues Revenues	4364000	USD
CY2013	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
CY2014	us-gaap	Cost Of Revenue CostOfRevenue	630000	USD
CY2015	us-gaap	Cost Of Revenue CostOfRevenue	730000	USD
CY2013	us-gaap	Gross Profit GrossProfit	0	USD
CY2014	us-gaap	Gross Profit GrossProfit	2893000	USD
CY2015	us-gaap	Gross Profit GrossProfit	3634000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29225000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27352000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24889000	USD
CY2013	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	26012000	USD
CY2014	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	22224000	USD
CY2015	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	20025000	USD
CY2013	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	3213000	USD
CY2014	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	5128000	USD
CY2015	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	4864000	USD
CY2013	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8051000	USD
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9228000	USD
CY2015	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7279000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-34063000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-28559000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-23670000	USD
CY2013	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1065000	USD
CY2014	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	4935000	USD
CY2015	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	3735000	USD
CY2013	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	391000	USD
CY2014	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	196000	USD
CY2015	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	123000	USD
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-674000	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4739000	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3612000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-27790000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-29943000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	58037000	USD
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.3
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.61
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	92368138	shares
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	92891846	shares
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	94922390	shares
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	1242000	USD
CY2013	us-gaap	Depreciation Depreciation	3539000	USD
CY2014	us-gaap	Depreciation Depreciation	3140000	USD
CY2013	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	264000	USD
CY2014	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-1446000	USD
CY2013	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	200000	USD
CY2014	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	140000	USD
CY2013	plx	Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement	58000	USD
CY2014	plx	Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement	22000	USD
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	886000	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2238000	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1006000	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3451000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	869000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1367000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1890000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	785000	USD
CY2014	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	90000	USD
CY2013	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	170000	USD
CY2014	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	137000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	66892000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	46000	USD
CY2013	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	226000	USD
CY2014	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-1395000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	34363000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-31631000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52035000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	86398000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54767000	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	112000	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	46000	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	534000	USD
CY2015	plx	Increase In Liabilities For Property Plant And Equipment IncreaseInLiabilitiesForPropertyPlantAndEquipment	489000	USD
CY2014	plx	Increase In Liabilities For Property Plant And Equipment IncreaseInLiabilitiesForPropertyPlantAndEquipment	120000	USD
CY2015	us-gaap	Interest Paid Net InterestPaidNet	3105000	USD
CY2014	us-gaap	Interest Paid Net InterestPaidNet	3079000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	10873000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1273000	USD
CY2015	plx	Share Based Compensation Restricted Stock Awards Net Of Forfeitures ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures	529000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	534000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	467000	USD
CY2014	plx	Share Based Compensation Restricted Stock Awards Net Of Forfeitures ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures	775000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	46000	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	112000	USD
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10675304	shares
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19778424	shares
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18850724	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1616000	USD
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1180000	USD
CY2015Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	0	USD
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1788000	USD
CY2015Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4587000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	3451000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	5767000	USD
CY2014Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	47000	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2202000	USD
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1667000	USD
CY2014Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	5100000	USD
CY2015Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	2073000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	65520000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	85881000	USD
CY2014Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1555000	USD
CY2015Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1628000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11282000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9744000	USD
CY2014Q4	us-gaap	Assets Assets	78357000	USD
CY2015Q4	us-gaap	Assets Assets	97253000	USD
CY2014Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3836000	USD
CY2015Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3629000	USD
CY2014Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	6802000	USD
CY2015Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	5534000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	886000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	504000	USD
CY2014Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation	52830000	USD
CY2015Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation	1568000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	64354000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11235000	USD
CY2014Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	67351000	USD
CY2015Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	67796000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	744000	USD
CY2014Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	2253000	USD
CY2015Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	2304000	USD
CY2015Q4	us-gaap	Other Long Term Notes Payable OtherLongTermNotesPayable	4301000	USD
CY2014Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	69604000	USD
CY2015Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	75145000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	133958000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	416000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	86380000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	371000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	94000	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	100000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	185633000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	194064000	USD
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	369000	USD
CY2015Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	408000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-241328000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-183291000	USD
CY2014Q4	us-gaap	Prepaid Royalties PrepaidRoyalties	1229000	USD
CY2015Q4	us-gaap	Prepaid Royalties PrepaidRoyalties	621000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	78357000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	97253000	USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	99800397	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	93603819	shares
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1125000	USD
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	99800397	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	93603819	shares
CY2014Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	3136000	USD
CY2015Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	3235000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	372000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	168000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	374000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	352000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Severance Payments DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments	185000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Severance Payments DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments	169000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	8658000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	28130000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	33451000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40111000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	37039000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2014Q4	plx	Other Assets Institutions Current OtherAssetsInstitutionsCurrent	124000	USD
CY2014Q4	plx	Other Assets Sundry Current OtherAssetsSundryCurrent	64000	USD
CY2015Q4	plx	Other Assets Sundry Current OtherAssetsSundryCurrent	51000	USD
CY2015Q4	plx	Other Assets Institutions Current OtherAssetsInstitutionsCurrent	216000	USD
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1243000	USD
CY2014Q4	us-gaap	Interest Payable Current InterestPayableCurrent	914000	USD
CY2015Q4	us-gaap	Interest Payable Current InterestPayableCurrent	914000	USD
CY2014Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1412000	USD
CY2015Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1406000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3113000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1571000	USD
CY2015Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	29000	USD
CY2014Q4	plx	Accounts Payable Property And Equipment Suppliers Current AccountsPayablePropertyAndEquipmentSuppliersCurrent	120000	USD
CY2015Q4	plx	Accounts Payable Property And Equipment Suppliers Current AccountsPayablePropertyAndEquipmentSuppliersCurrent	489000	USD
CY2015Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	49000000	USD
CY2013	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	888000	USD
CY2013	plx	Amortization Of Debt Issuance Costs AmortizationOfDebtIssuanceCosts	127000	USD
CY2014	plx	Amortization Of Debt Issuance Costs AmortizationOfDebtIssuanceCosts	444000	USD
CY2015	plx	Amortization Of Debt Issuance Costs AmortizationOfDebtIssuanceCosts	444000	USD
CY2014	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	3105000	USD
CY2015	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	3105000	USD
CY2013	us-gaap	Interest Expense InterestExpense	1015000	USD
CY2014	us-gaap	Interest Expense InterestExpense	3549000	USD
CY2015	us-gaap	Interest Expense InterestExpense	3549000	USD
CY2013Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0450	pure
CY2013Q3	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	66800000	USD
CY2013Q3	plx	Debt Instrument Convertible Conversion Share Number DebtInstrumentConvertibleConversionShareNumber	173.6593	shares
CY2013Q3	plx	Debt Instrument Convertible Base Value For Conversion Rate DebtInstrumentConvertibleBaseValueForConversionRate	1000	USD
CY2013Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	5.76
CY2013Q3	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2018-09-15
CY2014Q4	us-gaap	Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet	1884000	USD
CY2015Q4	us-gaap	Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet	1993000	USD
CY2014Q4	us-gaap	Disposal Group Including Discontinued Operation Inventory Current DisposalGroupIncludingDiscontinuedOperationInventoryCurrent	3216000	USD
CY2015Q4	us-gaap	Disposal Group Including Discontinued Operation Inventory Current DisposalGroupIncludingDiscontinuedOperationInventoryCurrent	80000	USD
CY2013	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	10479000	USD
CY2014	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	10128000	USD
CY2015	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	48674000	USD
CY2013	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	5428000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	32736000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	33547000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	21454000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	23803000	USD
CY2013	plx	Employee Severance Obligation Payment EmployeeSeveranceObligationPayment	194000	USD
CY2014	plx	Employee Severance Obligation Payment EmployeeSeveranceObligationPayment	195000	USD
CY2015	plx	Employee Severance Obligation Payment EmployeeSeveranceObligationPayment	168000	USD
CY2013	us-gaap	Postemployment Benefits Period Expense PostemploymentBenefitsPeriodExpense	1000000	USD
CY2015	us-gaap	Postemployment Benefits Period Expense PostemploymentBenefitsPeriodExpense	800000	USD
CY2013	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	801000	USD
CY2014	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	779000	USD
CY2015	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	675000	USD
CY2013	us-gaap	Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Loss Net Gain Loss Before Tax DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax	58000	USD
CY2014	us-gaap	Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Loss Net Gain Loss Before Tax DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax	22000	USD
CY2015	plx	Expected Severance Liabilities Payments For Future Period ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod	841000	USD
CY2014	us-gaap	Postemployment Benefits Period Expense PostemploymentBenefitsPeriodExpense	1000000	USD
CY2015	plx	Commitment Amount CommitmentAmount	800000	USD
CY2014	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	8423000	USD
CY2013	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-34737000	USD
CY2014	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-33298000	USD
CY2015	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-27282000	USD
CY2013	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	6947000	USD
CY2014	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	3355000	USD
CY2015	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	85319000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.38
CY2014	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.36
CY2015	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.29
CY2013	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.08
CY2014	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.04
CY2015	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.90
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6101000	USD
CY2014	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	3000	USD
CY2015	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	2000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-23997000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-29115000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-25770000	USD
CY2013	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-6656000	USD
CY2014	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-166000	USD
CY2015	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	1486000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30653000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29281000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24284000	USD
CY2014	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	11000	USD
CY2015	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3000	USD
CY2013	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	42000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-2102000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1001000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-512000	USD
CY2015	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	39899000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2102000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1001000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	39387000	USD
CY2013	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	66780000	USD
CY2015	plx	Proceeds From Issuance Of Common Stock Net Of Expenses ProceedsFromIssuanceOfCommonStockNetOfExpenses	6101000	USD
CY2015	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	7697000	USD
CY2013	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	6085000	USD
CY2014	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	3214000	USD
CY2015	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	46025000	USD
CY2013	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	334000	USD
CY2014	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	433000	USD
CY2015	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	564000	USD
CY2013	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	6947000	USD
CY2014	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	3355000	USD
CY2015	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	45420000	USD
CY2015	us-gaap	Discontinued Operation Provision For Loss Gain On Disposal Net Of Tax DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax	-39899000	USD
CY2013	plx	Disposal Group Including Discontinued Operation Share In Collaboration Agreement DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement	1034000	USD
CY2014	plx	Disposal Group Including Discontinued Operation Share In Collaboration Agreement DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement	1509000	USD
CY2015	plx	Disposal Group Including Discontinued Operation Share In Collaboration Agreement DisposalGroupIncludingDiscontinuedOperationShareInCollaborationAgreement	5048000	USD
CY2013	plx	Disposal Group Including Discontinued Operation Research And Development Expense DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense	-4088000	USD
CY2014	plx	Disposal Group Including Discontinued Operation Research And Development Expense DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense	-2409000	USD
CY2015	plx	Disposal Group Including Discontinued Operation Research And Development Expense DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense	-586000	USD
CY2013	plx	Disposal Group Including Discontinued Operation Grants And Reimbursements Received Or Receivable DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable	5284000	USD
CY2014	plx	Disposal Group Including Discontinued Operation Grants And Reimbursements Received Or Receivable DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable	2983000	USD
CY2015	plx	Disposal Group Including Discontinued Operation Grants And Reimbursements Received Or Receivable DisposalGroupIncludingDiscontinuedOperationGrantsAndReimbursementsReceivedOrReceivable	545000	USD
CY2013	plx	Disposal Group Including Discontinued Operation Research Development Expense Net DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet	1196000	USD
CY2014	plx	Disposal Group Including Discontinued Operation Research Development Expense Net DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet	574000	USD
CY2015	plx	Disposal Group Including Discontinued Operation Research Development Expense Net DisposalGroupIncludingDiscontinuedOperationResearchDevelopmentExpenseNet	-41000	USD
CY2013Q3	us-gaap	Debt Instrument Convertible Remaining Discount Amortization Period1 DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1	P5Y
CY2015Q4	us-gaap	Deferred Compensation Arrangement With Individual Recorded Liability DeferredCompensationArrangementWithIndividualRecordedLiability	200000	USD
CY2013	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	127000	USD
CY2014	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	444000	USD
CY2015	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	445000	USD
CY2015	plx	Revenue Recognized Over Designated Period RevenueRecognizedOverDesignatedPeriod	4600000	USD
CY2009Q4	us-gaap	Proceeds From Collaborators ProceedsFromCollaborators	60000000	USD
CY2009Q4	plx	Milestone Payment MilestonePayment	25000000	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4089000	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1242000	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1802000	USD
CY2006Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	13841655	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	760844	shares
CY2015Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1600000	USD
CY2015	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y
CY2013Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	66800000	USD
CY2015	dei	Document Type DocumentType	10-K
CY2015	dei	Amendment Flag AmendmentFlag	false
CY2015	dei	Document Period End Date DocumentPeriodEndDate	2015-12-31
CY2015	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2015	dei	Entity Registrant Name EntityRegistrantName	Protalix BioTherapeutics, Inc.
CY2015	dei	Entity Central Index Key EntityCentralIndexKey	0001006281
CY2015	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2015Q2	dei	Entity Public Float EntityPublicFloat	115000000	USD
CY2015	dei	Trading Symbol TradingSymbol	PLX
CY2015	plx	Tax Rate Assumption Related To Deferred Tax Difference Reversal TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal	39%, 26.5%, 25% and 0%
CY2016Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	99808238	shares
CY2014	us-gaap	Inventory Write Down InventoryWriteDown	100000	USD
CY2015	us-gaap	Inventory Write Down InventoryWriteDown	1300000	USD
CY2015	plx	Expected Defined Benefit Contribution During Period ExpectedDefinedBenefitContributionDuringPeriod	673000	USD
CY2013Q3	plx	Debt Instrument Principal Amount Related To Initial Purchaser Overallotment Option DebtInstrumentPrincipalAmountRelatedToInitialPurchaserOverallotmentOption	9000000	USD
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>c.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Use of estimates in the preparation of financial statements</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt 1in"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; FONT-SIZE: 10pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>l.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt"><b><font style="FONT-SIZE: 10pt">Concentration of credit risks and trade receivable</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits. The Company deposits these instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.75in"> <font style="FONT-SIZE: 10pt">The Company’s trade receivables represent amounts to be received from Pfizer and the Company’s customers in Israel. The Company does not require Pfizer or any of its Israeli customers to post collateral with respect to receivables. The Company performs periodic credit evaluations of Pfizer’s financial condition and believes there is no significant risk with respect to Pfizer’s payment of the receivables. As all Israeli customers are government entities, the Company believes there is no significant risk with respect to its receivables from such entities.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013	us-gaap	Notes Issued1 NotesIssued1	0	USD
CY2014	us-gaap	Notes Issued1 NotesIssued1	0	USD
CY2015	us-gaap	Notes Issued1 NotesIssued1	4301000	USD
CY2015	plx	Milestone Payment Amount Paid MilestonePaymentAmountPaid	0	USD
CY2014	plx	Milestone Payment Amount Paid MilestonePaymentAmountPaid	0	USD
CY2013	plx	Milestone Payment Amount Paid MilestonePaymentAmountPaid	0	USD
CY2015	us-gaap	Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Loss Net Gain Loss Before Tax DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax	-18000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6802000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5534000	USD
CY2015	plx	Milestone Potential Payable MilestonePotentialPayable	8700000	USD
CY2014Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	52830000	USD
CY2015Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	1568000	USD
CY2014Q4	us-gaap	Disposal Group Including Discontinued Operation Accounts Payable Current DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent	115000	USD
CY2014Q4	us-gaap	Disposal Group Including Discontinued Operation Other Current Liabilities DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities	8694000	USD
CY2014Q4	us-gaap	Disposal Group Including Discontinued Operation Deferred Revenue Current DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent	43109000	USD
CY2014Q4	plx	Disposal Group Including Discontinued Operation Liability In Connection With Collaboration Operation DisposalGroupIncludingDiscontinuedOperationLiabilityInConnectionWithCollaborationOperation	912000	USD
CY2015Q4	us-gaap	Disposal Group Including Discontinued Operation Other Current Liabilities DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities	1568000	USD

Files In Submission

Name	View Source	Status
0001144204-16-086642-index-headers.html	Edgar Link	pending
0001144204-16-086642-index.html	Edgar Link	pending
0001144204-16-086642.txt	Edgar Link	pending
0001144204-16-086642-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
plx-20151231.xml	Edgar Link	completed
plx-20151231.xsd	Edgar Link	pending
plx-20151231_cal.xml	Edgar Link	unprocessable
plx-20151231_def.xml	Edgar Link	unprocessable
plx-20151231_lab.xml	Edgar Link	unprocessable
plx-20151231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tlogo.jpg	Edgar Link	pending
tpg15b.jpg	Edgar Link	pending
tpg16.jpg	Edgar Link	pending
tpg52.jpg	Edgar Link	pending
tpg6.jpg	Edgar Link	pending
v432711_10k.htm	Edgar Link	pending
v432711_ex23-1.htm	Edgar Link	pending
v432711_ex3-10.htm	Edgar Link	pending
v432711_ex3-8.htm	Edgar Link	pending
v432711_ex3-9.htm	Edgar Link	pending
v432711_ex31-1.htm	Edgar Link	pending
v432711_ex31-2.htm	Edgar Link	pending
v432711_ex32-1.htm	Edgar Link	pending
v432711_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PLX
Protalix BioTherapeutics, Inc. Stock $plx

2016 Q1 Form 10-K Financial Statement

#000114420416086642 Filed on March 08, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX Protalix BioTherapeutics, Inc. Stock $plx

2016 Q1 Form 10-K Financial Statement

#000114420416086642 Filed on March 08, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX
Protalix BioTherapeutics, Inc. Stock $plx